Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
56%(5 trials)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_2
2
20%
Ph phase_3
4
40%
Ph phase_4
1
10%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
4(44.4%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 34 (44.4%)
Phase 41 (11.1%)
N/A1 (11.1%)

Trials by Status

withdrawn110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

NCT06382311
completedphase_3

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

NCT01551810
withdrawnnot_applicable

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

NCT00001080
completedphase_2

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

NCT02649192
completedphase_2

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06382311Phase 1

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Completed
NCT01551810Phase 3

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Completed
NCT00001080Not Applicable

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

Withdrawn
NCT02649192Phase 2

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

Completed
NCT00264576Phase 2

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Completed
NCT02675608

Vaccine Efficacy in Diabetic and Elderly Patients

Completed
NCT00700193Phase 3

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Completed
NCT00835926Phase 4

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Completed
NCT00885105Phase 3

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Completed
NCT00464672Phase 3

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10